Crispr Therapeutics AG vs NetApp Inc. — how do they compare? Crispr Therapeutics AG trades at $54.07 (market cap $5.23B), while NetApp Inc. trades at $199.49 (market cap $38.95B). The key difference: NetApp Inc. is far larger — about 7.4× Crispr Therapeutics AG's market cap, and NetApp Inc. pays a 1.05% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | NTAP | |
|---|---|---|
Market Cap | $5.23B | $38.95B |
Sector | Health | Technology |
52-Week High | $76.78 | $198.72 |
52-Week Low | $44.34 | $94.11 |
Enterprise Value | $3.65B | $38.10B |
Dividend Yield | — | 1.05% |
Trailing returns across standard periods
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →NetApp is a leading provider of enterprise data management and storage solutions. The company's three operating business units are products, software maintenance, and hardware maintenance. NetApp transitioned from a data center storage firm to a company with software data management solutions for multicloud environments. The California-headquartered company sells globally and has approximately 10,000 employees.
Read more on NTAP →